Insmed Inc., of Bridgewater, N.J., said data were published in the American Journal of Respiratory and Critical Care Medicine from a phase II study of Arikayce (liposomal amikacin for inhalation) in patients with nontuberculous mycobacterial lung infections who had been unable to achieve culture conversion to negative despite receiving a multidrug guideline-based regimen for six or more months.